PDA Virus Conference 2026

Topics we are looking for:

• 1. Regulatory Updates
  • International Perspectives
  • Global Pharmacopoeia and Guidance Chapters
  • Implementation of ICH Q5A(R2) Guideline
  • Regulatory Requirements for Virus Safety Testing and Virus Clearance Studies
  • Impact of Regulatory Requirements on the Pharmaceutical Industry
  • Inclusion of Next Generation Sequencing in Regulatory Submissions
• 2. Current and Emerging Viruses
  • Hepatitis E Virus
  • Parvoviruses
  • Coronaviruses
  • Zika
  • West Nile
  • Swine Flu/Avian Flu
  • Measles
  • Ebola
  • Mpox
  • Circovirus
  • Zoonoses
• 3. Virus Safety of Starting and Raw Materials
  • Risk Assessment
  • Virus-Like Particles
  • Case Studies for Media Treatment
  • New Threats to Human Plasma
  • Cell Culture Media Treatment/Cell Substrate Safety
  • Raw Materials and Material Selection
  • Substances of Human Origin and Animal-Derived Material
  • Supplier Audits and Qualification
  • Cell-Selection Antibodies
  • Serum and Trypsin
  • Antibody Drug Conjugates
  • Adventitious Viruses/Adventitious Agents
  • Prevention of Contamination
  • Utilization of Prior Knowledge
  • Plant-based Material
• 4. Viral Safety in Manufacturing
  • Case Studies and Experimental Data
  • Risk Assessment
  • Biopharmaceuticals
  • Plasma-Derived Medicinal Products
  • Viral Vaccines
  • Irradiation (Gamma, Electrons, X-rays)
  • Inactivation and Removal Performance
  • Filtration/Nanofiltration
  • Prion-Specific Filtration Methods
  • Viral Clearance Strategy: Removal, Inactivation, and Testing
  • Design Space for Process Optimization
  • Downstream Processes/Chromatography
  • Sustainable Detergents
  • Precipitation
  • Prior Knowledge and Risk Assessments
  • Continuous Manufacturing/Continuous Processing
  • Platform Approach
  • Impact of PFAS Regulation
  • Technical Developments/Innovation/Emergent Technology
  • Integrated Recycling Process
  • Reduction of Wastewater
  • Waste Prevention and Handling
  • Environmental Protection
  • Recycling Economy
  • Data Acquisition and Standardization
• 5. Virus Testing
  • Virus Detection Methods
  • Virus-Like/Noninfectious Particles
  • Development of Alternative and Rapid Test Methods
  • Next Generation Sequencing/High Throughput Sequencing
  • Technical Operation of Platforms (e.g., Assay Automation, Time to Result, Validation)
  • Bioinformatics, Data Analytics, and Application of Artificial Intelligence
  • In-silico Standards for Bioinformatics Software
  • Machine/Deep Learning on Virus Sequences
  • Targeted vs. Non-Targeted Next Generation Sequencing
  • Product-Enhanced Reverse Transcriptase Assay
  • Nucleic Acid-Based Methods
  • Digital Polymerase Chain Reaction
  • Model Organisms, Equipment, and Conditions
  • Replacing In-Vivo Assays and the 3R Initiative
  • Replacing/Complementing In-Vitro Assays
  • Cell-Based Assays/Hepatitis E Virus Infectivity Assay
  • Emerging and Hard-to-Detect Viruses
  • Transmission Electron Microscopy
• 6. Viral Safety of ATMPs and Modern Therapies
  • Human Platelet Lysates and Sera
  • Viral Vectors/Viral Vector Products
  • Virus Panels/Virus Selection
  • Virus Safety for Different Cell Lines
  • Helper Virus Production
  • Viral Clearance and Viral Vector Purification Processes
  • Case Studies for Cell and Gene-Based Medicinal Products
  • Considerations for Induced Pluripotent Stem Cell Therapies
  • Extracellular Vesicles
  • Risk Management Strategies
  • Transplantation and Xenotransplantation
  • Reduction of Vein-to-Vein Time
  • Application in Medical Devices
• 7. TSE Contamination and Risk Mitigation
  • Raw Materials
  • Blood/Plasma Products
  • Cell-Based Products
  • Cell Substrates and Their Infectability
  • New Concepts for Testing and Identification
  • Inactivation Strategies and Equipment
• 8. Aspects of Food and Waterborne Virus Safety
  • Norovirus-Related Diseases
  • Rotavirus-Related Diseases
  • Identification of Viruses in Food Matrices
  • Cultured Meat Products
  • Transmission Pathways
  • Risk Assessments
• 9. Virus Reduction Studies
  • Virus Safety Strategies
  • Usage of Prior Knowledge
  • Design of Studies and Design of Experiment Studies
  • Platform Validation Including Modular Claims
  • Mechanism of Action of Virus Removal/Inactivation
  • Robustness of Specific Unit Operations
  • Identification of Critical Process Parameters
  • Spike Preparations
  • Co-Spiking Studies
  • Scalability of Study Design and Results
  • Sanitization of Chromatographic Equipment
  • Columns Including Virus Carry-Over Studies
  • Impact of Virus Spike Quality
  • Developments in Laboratory Automation
  • Viral Reduction in Alternative Cell Types